Legesse 2004.

Methods	Design: parallel group randomized trial Duration of study: March 2003 Follow‐up: 21 days
Participants	Country: Ethiopia Setting: school Number included in study: 661 Age: 6–19 years (mean 10.6 years) Sex: female 254, male 280 Inclusion criteria: did not receive any anthelmintic drugs in the past 3 months; positive for ≥ 1 helminth infections Exclusion criteria: not reported Lost at follow‐up: 127 (19.2%) Number positive for A lumbricoides: 432 Number included in review: 432
Interventions	Treatment strategy: screening and treat all included participants Group 1: mebendazole 100 mg twice a day for 3 days (n = 325) Group 2: albendazole 400 mg single dose (n = 107)
Outcomes	Outcomes included:Ascaris prevalence pre‐ and post‐treatment, cure rates, pre‐ and post‐treatment GM epg, ERR Outcomes not included in review: anthelmintic efficacy for Trichuris andS mansoni
Notes	Diagnostic technique: Kato‐Katz Funding support: mebendazole donated by Dr AR Hashim, Manager of East African Pharmaceuticals in Addis Ababa.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "A sequentially numbered list of students positive for at least one of the two helminth infections (Ascariasis or Trichuriasis) was prepared and randomly divided into four treatment groups using random numbers obtained from a random number table."
Allocation concealment (selection bias)	Unclear risk	Details not reported.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Different treatment schedule.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Details not reported.
Incomplete outcome data (attrition bias) All outcomes	High risk	127 (19.2%) participants lost at follow‐up and not included in analysis. Balanced lost among groups.
Selective reporting (reporting bias)	High risk	Adverse events not reported.
Other bias	Low risk	No other obvious source of bias.